Pharmacokinetic Bioequivalence, Safety, and Immunogenicity of DMB-3111, a Trastuzumab Biosimilar, and Trastuzumab in Healthy Japanese Adult Males: Results of a Randomized Trial
Crossref DOI link: https://doi.org/10.1007/s40259-015-0153-2
Published Online: 2015-12-21
Published Print: 2016-02
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Morita, Jun
Tanaka, Masashi
Nomoto, Masahiro
Matsuki, Shunji
Tsuru, Tomomi
Matsuguma, Kyoko
Shiramoto, Masanari
Funding for this research was provided by:
Meiji Seika Pharma (JP)
Dong A Socio Holdings
License valid from 2015-12-21